Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02601716 · ClinicalTrials.gov registry record · Phase 2
PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults
A Phase 2 study, sponsored by Sanaria.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT02601716 is a Phase 2 study that has completed, run by Sanaria. The registered enrollment target is 92 participants.
The verdict
NCT02601716, a Phase 2 study, has completed, sponsored by Sanaria.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is an open-label evaluation of the safety, tolerability, immunogenicity and efficacy of PfSPZ Vaccine administered by direct venous inoculation (DVI) in healthy, malaria-naïve adult subjects.
Interventions
- BIOLOGICAL PfSPZ Vaccine
- BIOLOGICAL CHMI (7G8)
- BIOLOGICAL CHMI (NF135.C10)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02601716
The ClinicalTrials.gov registry entry for NCT02601716 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanaria, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PfSPZ Vaccine is the first listed.
NCT02601716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02601716 about?
NCT02601716 is a clinical study titled "PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults". This is an open-label evaluation of the safety, tolerability, immunogenicity and efficacy of PfSPZ Vaccine administered by direct venous inoculation (DVI) in healthy, malaria-naïve adult subjects.
What is the current status of trial NCT02601716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2016-01. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02601716?
The interventions under investigation include: PfSPZ Vaccine (BIOLOGICAL), CHMI (7G8) (BIOLOGICAL), CHMI (NF135.C10) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02601716?
This trial is sponsored by Sanaria, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.